Lunai Bioworks Inc. Common Stock

LNAINASDAQUSD
0.31 USD
0.00 (0.00%)AT CLOSE (11:59 AM EDT)
0.28
0.03 (9.06%)
POST MARKET (AS OF 08:00 PM EDT)
Post Market
AS OF 08:00 PM EDT
0.28
0.03 (9.06%)
🔴Market: CLOSED
Open?$0.31
High?$0.33
Low?$0.29
Prev. Close?$0.31
Volume?29.9M
Avg. Volume?38.9M
VWAP?$0.35
Rel. Volume?0.77x
Bid / Ask
Bid?$0.31 × 100
Ask?$40.00 × 500
Spread?$39.69
Midpoint?$20.15
Valuation & Ratios
Market Cap?11.2M
Shares Out?36.3M
Float?14.8M
Float %?61.2%
P/E Ratio?N/A
P/B Ratio?-0.83
EPS?-$3.46
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?0.03Weak
Quick Ratio?0.03Weak
Cash Ratio?0.02Low
Debt/Equity?-0.10Low
ValuationATTRACTIVELY VALUED
Score
100/100
P/E?
N/A
P/B?
-0.83CHEAP
P/S?
N/A
P/FCF?
N/A
EV/EBITDA?
-1.0CHEAP
EV/Sales?
N/A
Returns & Efficiency
ROE?
926.5%STRONG
ROA?
-1,882.9%WEAK
Cash Flow & Enterprise
FCF?$-5720156
Enterprise Value?$12.1M
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
Employees
29
Market Cap
11.2M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2014-11-18
Address
CENTURY CITY MEDICAL PLAZA
SUITE 906 LOS ANGELES, CA 90067
Phone: 45 39179840